Javascript must be enabled to continue!
Unveiling Impurities: A Comprehensive RP-HPLC Method for Accurate Atorvastatin Impurity Analysis in Pharmaceuticals Using an Accuracy Profile Approach
View through CrossRef
Abstract
Background
Accurate determination of active pharmaceutical ingredients and impurities is essential for ensuring the safety and effectiveness of medications. This study focuses on the validation of a high-performance liquid chromatography (HPLC) method for quantifying atorvastatin and its impurities, addressing a critical aspect of pharmaceutical analysis.
Objective
The primary objective is to conduct a comprehensive validation study for the HPLC method, covering specificity assessment, response function establishment, and a detailed analysis of precision, trueness, and tolerance intervals. The emphasis is on demonstrating the method’s precision, accuracy, and stability-indicating capabilities across various concentrations and compounds.
Methods
The HPLC method is validated through rigorous assessments, including specificity, response function establishment, and analyses of precision, trueness, and tolerance intervals. Induced degradation experiments are conducted to explore atorvastatin’s behavior under extreme conditions. Insights into the compound’s synthesis and degradation pathways are provided through a proposed mechanism for intramolecular esterification.
Results
The results affirm the precision, accuracy, and stability-indicating capabilities of the validated HPLC method. The method effectively differentiates between atorvastatin and its impurities, showcasing its suitability for pharmaceutical quality control.
Conclusions
The validated HPLC method emerges as a robust and reliable tool for atorvastatin analysis, contributing significantly to pharmaceutical research and quality control. Its application ensures the safety and efficacy of medications, reinforcing its role in pharmaceutical analysis.
Highlights
This study not only validates a crucial HPLC method for atorvastatin analysis but also provides insights into the compound’s behavior under extreme conditions and its synthesis and degradation pathways. The validated method serves as a cornerstone in pharmaceutical research and quality control, ensuring medication safety and efficacy.
Title: Unveiling Impurities: A Comprehensive RP-HPLC Method for Accurate Atorvastatin Impurity Analysis in Pharmaceuticals Using an Accuracy Profile Approach
Description:
Abstract
Background
Accurate determination of active pharmaceutical ingredients and impurities is essential for ensuring the safety and effectiveness of medications.
This study focuses on the validation of a high-performance liquid chromatography (HPLC) method for quantifying atorvastatin and its impurities, addressing a critical aspect of pharmaceutical analysis.
Objective
The primary objective is to conduct a comprehensive validation study for the HPLC method, covering specificity assessment, response function establishment, and a detailed analysis of precision, trueness, and tolerance intervals.
The emphasis is on demonstrating the method’s precision, accuracy, and stability-indicating capabilities across various concentrations and compounds.
Methods
The HPLC method is validated through rigorous assessments, including specificity, response function establishment, and analyses of precision, trueness, and tolerance intervals.
Induced degradation experiments are conducted to explore atorvastatin’s behavior under extreme conditions.
Insights into the compound’s synthesis and degradation pathways are provided through a proposed mechanism for intramolecular esterification.
Results
The results affirm the precision, accuracy, and stability-indicating capabilities of the validated HPLC method.
The method effectively differentiates between atorvastatin and its impurities, showcasing its suitability for pharmaceutical quality control.
Conclusions
The validated HPLC method emerges as a robust and reliable tool for atorvastatin analysis, contributing significantly to pharmaceutical research and quality control.
Its application ensures the safety and efficacy of medications, reinforcing its role in pharmaceutical analysis.
Highlights
This study not only validates a crucial HPLC method for atorvastatin analysis but also provides insights into the compound’s behavior under extreme conditions and its synthesis and degradation pathways.
The validated method serves as a cornerstone in pharmaceutical research and quality control, ensuring medication safety and efficacy.
Related Results
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
Abstract
Background
SUL-DUR is a β-lactam/β-lactamase inhibitor combination in development for the treatment of ABC infections, ...
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
Abstract
Background
Epetraborole (EBO) is an orally available, bacterial leucyl transfer RNA synthetase inhibitor that concentra...
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
Abstract
Background
Epetraborole (EBO), an orally available bacterial leucyl transfer RNA synthetase inhibitor with potent activ...
592. Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA)
592. Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA)
Abstract
Background
Given the increasing prevalence of non-albicans Candida species, including C. glabrata and C. auris, which h...
A digitized impurity database analysis method for determining the impurity profiles of gatifloxacin in bulk materials and injections
A digitized impurity database analysis method for determining the impurity profiles of gatifloxacin in bulk materials and injections
HPLC has become the most important analytical technique for impurity profiling in order to assure the quality of pharmaceutical products. Although HPLC is considered as a well-esta...
Identify and Assess Drug Interactions with Atorvastatin in Inpatient Care
Identify and Assess Drug Interactions with Atorvastatin in Inpatient Care
Background: Atorvastatin is a recent HMG-COA reductase inhibitor used to treat primary hypercholesterolemia, homozygous familial hypercholesterolemia, and mixed dyslipidemias. It i...
Regulatory aspects of Impurity profiling
Regulatory aspects of Impurity profiling
Quality, safety and efficacy of pharmaceuticals play an important role in drug therapy. The safety attribute of drug is established by its pharmacological or toxicological profile ...
Influence of Impurity Concentration on Plasma Confinement in D-3He Fusion Reaction
Influence of Impurity Concentration on Plasma Confinement in D-3He Fusion Reaction
Plasma confinement along with ash and impurity existence in magnetic fusion devices has been a challenge for researchers. By employing a 0-dimensional model containing power balanc...

